Compare GIFT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIFT | RLYB |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 28.7M |
| IPO Year | N/A | 2021 |
| Metric | GIFT | RLYB |
|---|---|---|
| Price | $1.11 | $0.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 61.0K | ★ 167.1K |
| Earning Date | 11-10-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $86,142,442.00 | $674,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $0.82 | $0.22 |
| 52 Week High | $2.38 | $0.95 |
| Indicator | GIFT | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 48.58 |
| Support Level | $1.03 | $0.58 |
| Resistance Level | $1.15 | $0.74 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 41.67 | 62.00 |
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.